Suppr超能文献

铜死亡相关基因FDX1作为肾透明细胞癌的预后生物标志物,与免疫检查点和免疫细胞浸润相关。

Cuproptosis-related gene FDX1 as a prognostic biomarker for kidney renal clear cell carcinoma correlates with immune checkpoints and immune cell infiltration.

作者信息

Yao Yimin, Chen Haixin, Lou Minjun, Chen Tingting

机构信息

Medical Laboratory, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine), Hangzhou, China.

The First Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China.

出版信息

Front Genet. 2023 Jan 23;14:1071694. doi: 10.3389/fgene.2023.1071694. eCollection 2023.

Abstract

Kidney renal clear cell carcinoma (KIRC) is not sensitive to radiotherapy and chemotherapy, and only some KIRC patients can benefit from immunotherapy and targeted therapy. Cuproptosis is a new mechanism of cell death, which is closely related to tumor progression, prognosis and immunity. The identification of prognostic markers related to cuproptosis in KIRC may provide targets for treatment and improve the prognosis of KIRC patients. Ten cuproptosis-related genes were analyzed for differential expression in KIRC-TCGA and a prognostic model was constructed. Nomogram diagnostic model was used to screen independent prognostic molecules. The screened molecules were verified in multiple datasets (GSE36895 and GSE53757), and in KIRC tumor tissues by RT-PCR and immunohistochemistry (IHC). Clinical correlation of cuproptosis-related independent prognostic molecules was analyzed. According to the molecular expression, the two groups were divided into high and low expression groups, and the differences of immune checkpoint and tumor infiltrating lymphocytes (TILs) between the two groups were compared by EPIC algorithm. The potential Immune checkpoint blocking (ICB) response of high and low expression groups was predicted by the "TIDE" algorithm. FDX1 and DLAT were protective factors, while CDKN2A was a risk factor. FDX1 was an independent prognostic molecule by Nomogram, and low expressed in tumor tissues compared with adjacent tissues ( < 0.05). FDX1 was positively correlated with CD274, HAVCR2, PDCD1LG2, and negatively correlated with CTLA4, LAG3, and PDCD1. The TIDE score of low-FDX1 group was higher than that of high-FDX1 group. The abundance of CD4 T cells, CD8 T cells and Endothelial cells in FDX1-low group was lower than that in FDX1-high group ( < 0.05). FDX1, as a key cuproptosis-related gene, was also an independent prognostic molecule of KIRC. FDX1 might become an interesting biomarker and potential therapeutic target for KIRC.

摘要

肾透明细胞癌(KIRC)对放疗和化疗不敏感,只有部分KIRC患者能从免疫治疗和靶向治疗中获益。铜死亡是一种新的细胞死亡机制,与肿瘤进展、预后及免疫密切相关。鉴定KIRC中与铜死亡相关的预后标志物可为治疗提供靶点并改善KIRC患者的预后。对10个与铜死亡相关的基因在KIRC-TCGA中进行差异表达分析并构建预后模型。使用列线图诊断模型筛选独立预后分子。对筛选出的分子在多个数据集(GSE36895和GSE53757)以及通过RT-PCR和免疫组织化学(IHC)在KIRC肿瘤组织中进行验证。分析与铜死亡相关的独立预后分子的临床相关性。根据分子表达将两组分为高表达组和低表达组,通过EPIC算法比较两组之间免疫检查点和肿瘤浸润淋巴细胞(TILs)的差异。用“TIDE”算法预测高表达组和低表达组潜在的免疫检查点阻断(ICB)反应。FDX1和DLAT是保护因素,而CDKN2A是危险因素。通过列线图分析FDX1是独立预后分子,与癌旁组织相比在肿瘤组织中低表达(<0.05)。FDX1与CD274、HAVCR2、PDCD1LG2呈正相关,与CTLA4、LAG3和PDCD1呈负相关。低FDX1组的TIDE评分高于高FDX1组。FDX1低表达组中CD4 T细胞、CD8 T细胞和内皮细胞的丰度低于FDX1高表达组(<0.05)。FDX1作为关键的铜死亡相关基因,也是KIRC的独立预后分子。FDX1可能成为KIRC一个有趣的生物标志物和潜在治疗靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/85f0/9900009/457a00e0fe9a/fgene-14-1071694-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验